Valproic acid as anti-cancer drug

被引：87

作者：

Michaelis, Martin ^{[1
]}

Doerr, Hans Wilhelm ^{[1
]}

Cinatl, Jindrich, Jr. ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Inst Med Virol, Zentrum Hyg, D-6000 Frankfurt, Germany

来源：

CURRENT PHARMACEUTICAL DESIGN | 2007年 / 13卷 / 33期

关键词：

valproic acid; HDAC; differentiation; angiogenesis; combination therapy; clinical studies; HISTONE DEACETYLASE INHIBITORS; TRANS-RETINOIC ACID; ACUTE MYELOID-LEUKEMIA; ACTIVATED-RECEPTOR-GAMMA; PROSTATE-SPECIFIC ANTIGEN; ACUTE MYELOGENOUS LEUKEMIA; FETAL HEMOGLOBIN-SYNTHESIS; APOPTOSIS-INDUCING LIGAND; PML NUCLEAR-BODIES; CANCER CELL-GROWTH;

D O I：

10.2174/138161207782360519

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.

引用

页码：3378 / 3393

页数：16

共 50 条

[1] Anti-cancer drug - Preface
Bergmann-Leitner, ES
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (19)
[2] Anti-Cancer Drug Delivery System
Li Yan
Huang Wei
Huang Ping
Zhu Xinyuan
Yan Deyue
PROGRESS IN CHEMISTRY, 2014, 26 (08) : 1395 - 1408
[3] MACROMOLECULE ANTI-CANCER DRUG CONJUGATES
KATO, Y
HARA, T
JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1983, 41 (12) : 1135 - 1142
[4] Mitosis as an anti-cancer drug target
Anna-Leena Salmela
Marko J. Kallio
Chromosoma, 2013, 122 : 431 - 449
[5] FTORAFUR - NEW ANTI-CANCER DRUG
BRENNER, H
CHAITCHIK, S
BRENNER, J
DIGESTION, 1977, 16 (03) : 233 - 233
[6] CISPLATIN - NEW ANTI-CANCER DRUG
ROZENCWEIG, M
ABELE, R
BEDOGNI, P
KENIS, Y
LOUVAIN MEDICAL, 1979, 98 (10): : 679 - 684
[7] Mitosis as an anti-cancer drug target
Salmela, Anna-Leena
Kallio, Marko J.
CHROMOSOMA, 2013, 122 (05) : 431 - 449
[8] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
Shoyo Shibata
Maiko Matsushita
Yoshimasa Saito
Takeshi Suzuki
Therapeutic Innovation & Regulatory Science, 2018, 52 : 442 - 448
[9] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
Shibata, Shoyo
Matsushita, Maiko
Saito, Yoshimasa
Suzuki, Takeshi
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (04) : 442 - 448
[10] METFORMIN - FROM ANTI-DIABETIC DRUG TO ANTI-CANCER DRUG
Markowicz-Piasecka, Magdalena
Huttunen, Kristiina M.
Mikiciuk-Olasik, Elzbieta
Mateusiak, Lukasz
Sikora, Joanna
ACTA POLONIAE PHARMACEUTICA, 2018, 75 (01): : 3 - 18

← 1 2 3 4 5 →